130 related articles for article (PubMed ID: 33077933)
1. Intra-cisterna magna delivery of an AAV vector with the GLUT1 promoter in a pig recapitulates the physiological expression of SLC2A1.
Nakamura S; Osaka H; Muramatsu SI; Takino N; Ito M; Jimbo EF; Watanabe C; Hishikawa S; Nakajima T; Yamagata T
Gene Ther; 2021 Jun; 28(6):329-338. PubMed ID: 33077933
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for Glut1-deficient mouse using an adeno-associated virus vector with the human intrinsic GLUT1 promoter.
Nakamura S; Muramatsu SI; Takino N; Ito M; Jimbo EF; Shimazaki K; Onaka T; Ohtsuki S; Terasaki T; Yamagata T; Osaka H
J Gene Med; 2018 Apr; 20(4):e3013. PubMed ID: 29624790
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome.
Nakamura S; Osaka H; Muramatsu SI; Takino N; Ito M; Aoki S; Jimbo EF; Shimazaki K; Onaka T; Ohtsuki S; Terasaki T; Yamagata T
Mol Genet Metab Rep; 2017 Mar; 10():67-74. PubMed ID: 28119822
[TBL] [Abstract][Full Text] [Related]
4. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna.
Taghian T; Marosfoi MG; Puri AS; Cataltepe OI; King RM; Diffie EB; Maguire AS; Martin DR; Fernau D; Batista AR; Kuchel T; Christou C; Perumal R; Chandra S; Gamlin PD; Bertrand SG; Flotte TR; McKenna-Yasek D; Tai PWL; Aronin N; Gounis MJ; Sena-Esteves M; Gray-Edwards HL
Mol Ther; 2020 Feb; 28(2):411-421. PubMed ID: 31813800
[TBL] [Abstract][Full Text] [Related]
5. Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.
Bailey RM; Rozenberg A; Gray SJ
Brain Res; 2020 Jul; 1739():146832. PubMed ID: 32289279
[TBL] [Abstract][Full Text] [Related]
6. Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9.
Chatterjee D; Marmion DJ; McBride JL; Manfredsson FP; Butler D; Messer A; Kordower JH
Gene Ther; 2022 Jun; 29(6):390-397. PubMed ID: 33753910
[TBL] [Abstract][Full Text] [Related]
7. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.
Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL
Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242
[TBL] [Abstract][Full Text] [Related]
8. A Single Vector Platform for High-Level Gene Transduction of Central Neurons: Adeno-Associated Virus Vector Equipped with the Tet-Off System.
Sohn J; Takahashi M; Okamoto S; Ishida Y; Furuta T; Hioki H
PLoS One; 2017; 12(1):e0169611. PubMed ID: 28060929
[TBL] [Abstract][Full Text] [Related]
9. Atrial-Specific Gene Delivery Using an Adeno-Associated Viral Vector.
Ni L; Scott L; Campbell HM; Pan X; Alsina KM; Reynolds J; Philippen LE; Hulsurkar M; Lagor WR; Li N; Wehrens XHT
Circ Res; 2019 Jan; 124(2):256-262. PubMed ID: 30582449
[TBL] [Abstract][Full Text] [Related]
10. Motor neuron transduction after intracisternal delivery of AAV9 in a cynomolgus macaque.
Bell P; Hinderer C; Louboutin JP; Yu H; Grant R; Bote E; Wilson JM
Hum Gene Ther Methods; 2015 Apr; 26(2):43-4. PubMed ID: 25885277
[TBL] [Abstract][Full Text] [Related]
11. Transduction Profile of the Marmoset Central Nervous System Using Adeno-Associated Virus Serotype 9 Vectors.
Matsuzaki Y; Konno A; Mukai R; Honda F; Hirato M; Yoshimoto Y; Hirai H
Mol Neurobiol; 2017 Apr; 54(3):1745-1758. PubMed ID: 26884266
[TBL] [Abstract][Full Text] [Related]
12. Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-beta promoter.
Wang CY; Guo HY; Lim TM; Ng YK; Neo HP; Hwang PY; Yee WC; Wang S
J Gene Med; 2005 Jul; 7(7):945-55. PubMed ID: 15756650
[TBL] [Abstract][Full Text] [Related]
13. [Expression pattern of different serotypes of adeno-associated viral vectors in mouse retina].
Hu S; Yang LP
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):845-850. PubMed ID: 33047717
[TBL] [Abstract][Full Text] [Related]
14. Targeting transgene to the heart and liver with AAV9 by different promoters.
Chen BD; He CH; Chen XC; Pan S; Liu F; Ma X; Li XM; Gai MT; Tao J; Ma YT; Yang YN; Gao XM
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1108-17. PubMed ID: 26173818
[TBL] [Abstract][Full Text] [Related]
15. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.
Gray SJ; Nagabhushan Kalburgi S; McCown TJ; Jude Samulski R
Gene Ther; 2013 Apr; 20(4):450-9. PubMed ID: 23303281
[TBL] [Abstract][Full Text] [Related]
16. Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.
Hammond SL; Leek AN; Richman EH; Tjalkens RB
PLoS One; 2017; 12(12):e0188830. PubMed ID: 29244806
[TBL] [Abstract][Full Text] [Related]
17. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease.
Bucher T; Colle MA; Wakeling E; Dubreil L; Fyfe J; Briot-Nivard D; Maquigneau M; Raoul S; Cherel Y; Astord S; Duque S; Marais T; Voit T; Moullier P; Barkats M; Joussemet B
Hum Gene Ther; 2013 Jul; 24(7):670-82. PubMed ID: 23799774
[TBL] [Abstract][Full Text] [Related]
18. Ocular gene transfer with self-complementary AAV vectors.
Yokoi K; Kachi S; Zhang HS; Gregory PD; Spratt SK; Samulski RJ; Campochiaro PA
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3324-8. PubMed ID: 17591905
[TBL] [Abstract][Full Text] [Related]
19. Glial promoter selectivity following AAV-delivery to the immature brain.
von Jonquieres G; Mersmann N; Klugmann CB; Harasta AE; Lutz B; Teahan O; Housley GD; Fröhlich D; Krämer-Albers EM; Klugmann M
PLoS One; 2013; 8(6):e65646. PubMed ID: 23799030
[TBL] [Abstract][Full Text] [Related]
20. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
